NanJing Pharmaceutical Company Limited

XSSC:600713 Stock Report

Market Cap: CN¥6.3b

NanJing Pharmaceutical Past Earnings Performance

Past criteria checks 4/6

NanJing Pharmaceutical has been growing earnings at an average annual rate of 12.6%, while the Healthcare industry saw earnings growing at 2% annually. Revenues have been growing at an average rate of 9.1% per year. NanJing Pharmaceutical's return on equity is 9.9%, and it has net margins of 1.1%.

Key information

12.6%

Earnings growth rate

6.8%

EPS growth rate

Healthcare Industry Growth7.0%
Revenue growth rate9.1%
Return on equity9.9%
Net Margin1.1%
Next Earnings Update10 Apr 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How NanJing Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

XSSC:600713 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2453,9815791,69438
30 Jun 2453,4795811,68141
31 Mar 2453,4605881,68238
31 Dec 2353,5905781,67436
30 Sep 2353,3325661,74034
30 Jun 2353,6245711,73432
31 Mar 2352,6036121,74131
31 Dec 2250,2225961,72027
30 Sep 2249,1636291,62526
30 Jun 2247,1676161,58624
31 Mar 2245,7395361,54721
31 Dec 2145,1235051,52021
30 Sep 2144,1404401,45722
30 Jun 2143,4424261,46418
31 Mar 2142,1134021,45516
31 Dec 2039,8173761,40316
30 Sep 2038,5383351,42514
30 Jun 2037,5143601,38115
31 Mar 2037,2093511,36416
31 Dec 1937,1563471,37013
30 Sep 1935,7453601,37013
30 Jun 1934,0622851,29912
31 Mar 1932,2822721,24412
31 Dec 1831,3032641,20011
30 Sep 1831,6082581,2818
30 Jun 1830,4732591,2276
31 Mar 1829,8842371,2172
31 Dec 1728,8102321,1672
30 Sep 1727,4522259761
30 Jun 1727,2532119631
31 Mar 1726,8311919590
31 Dec 1626,7211809550
30 Sep 1626,1571649860
30 Jun 1625,7861589640
31 Mar 1625,4901589370
31 Dec 1524,8131579280
30 Sep 1524,0091998880
30 Jun 1523,3271849000
31 Mar 1522,7191678910
31 Dec 1422,0761298850
30 Sep 1421,311658390
30 Jun 1420,505468610
31 Mar 1419,828448280

Quality Earnings: 600713 has high quality earnings.

Growing Profit Margin: 600713's current net profit margins (1.1%) are higher than last year (1.1%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 600713's earnings have grown by 12.6% per year over the past 5 years.

Accelerating Growth: 600713's earnings growth over the past year (2.4%) is below its 5-year average (12.6% per year).

Earnings vs Industry: 600713 earnings growth over the past year (2.4%) exceeded the Healthcare industry -5.7%.

Return on Equity

High ROE: 600713's Return on Equity (9.9%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/23 03:24
End of Day Share Price 2025/01/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

NanJing Pharmaceutical Company Limited is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Liang LiangFirst Capital Securities Co. LTD.
Wen Liang CuiFounder Securities Co., Ltd.
Weina JiangGuosen Securities Co., Ltd.